NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE

Post-LOE

nicardipine hydrochloride

Chiesi

ANDAINTRAVENOUSINJECTABLE

Approved

Apr 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE (nicardipine hydrochloride) by Chiesi is concentrations. Approved for hypertension, hypertension. First approved in 2024.

Drug data last refreshed 20h ago

Mechanism of Action

concentrations. The contractile processes of cardiac muscle and vascular smooth muscle are dependent upon the movement of extracellular calcium ions into these cells through specific ion channels. The effects of nicardipine are more selective to vascular smooth muscle than cardiac muscle. In animal…

Indications (1)

hypertension

Company

Worked on NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE at Chiesi? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.